Marginal zone lymphoma (MZL) is a slow-growing B-cell lymphoma that often responds well to treatment, and many patients live for decades after diagnosis. How it’s treated depends almost entirely on which of the three subtypes you have and whether the disease is localized or has spread. Some people don’t need treatment right away at all. Others benefit from targeted radiation, antibiotics, immunotherapy, chemotherapy combinations, or newer targeted drugs.
The Three Subtypes Shape Everything
MZL comes in three distinct forms, each named for where it starts. Extranodal MZL (also called MALT lymphoma) develops in organs outside the lymph nodes, most commonly the stomach but also the lungs, eyes, skin, and thyroid. Nodal MZL starts in the lymph nodes themselves. Splenic MZL originates in the spleen and often involves the bone marrow and blood.
All three subtypes share certain features under the microscope: the lymphoma cells typically test negative for two surface markers (CD5 and CD10), which helps distinguish MZL from other lymphomas that can look similar. But the subtypes differ in how they behave, what triggers them, and how they’re best managed. Getting the subtype right is the first step toward the right treatment plan.
When Treatment Can Wait
Not everyone with MZL needs treatment immediately. If you have no symptoms, your spleen isn’t enlarged, and your blood counts are stable, your doctor may recommend a strategy called watchful waiting. This is particularly common in splenic MZL and in advanced-stage nodal or extranodal disease that isn’t causing problems. The triggers that typically signal it’s time to start treatment include symptomatic splenomegaly (a spleen large enough to cause discomfort or fullness), worsening blood counts like anemia or low platelets, systemic symptoms such as fevers, night sweats, or unintentional weight loss, and progressive enlargement of lymph nodes.
Watchful waiting isn’t neglect. It involves regular checkups and blood work so your care team can catch changes early. Many patients stay on observation for years before needing any therapy.
Gastric MALT: Antibiotics Come First
Stomach MALT lymphoma stands apart from every other form of MZL because it’s often driven by a bacterial infection. The bacterium Helicobacter pylori causes chronic inflammation in the stomach lining, and over time that inflammation can trigger lymphoma growth. Because of this link, the first-line treatment for gastric MALT lymphoma is antibiotic therapy to eradicate the infection, typically a combination of a proton pump inhibitor, clarithromycin, and amoxicillin taken for 7 to 14 days.
This approach works even in some patients who test negative for the infection, though the reasons aren’t fully understood. After completing antibiotics, follow-up endoscopy with biopsies is performed at around six months, then every three to six months afterward. The lymphoma can take a long time to fully regress, and guidelines suggest waiting at least 12 months before concluding that antibiotics didn’t work, as long as the disease isn’t visibly progressing. Rushing to additional treatment isn’t necessary when the lymphoma is stable and slowly shrinking.
Localized Disease: Radiation Works Well
For non-gastric MALT lymphoma that’s confined to one site, and for early-stage nodal MZL, involved-site radiation therapy is the preferred treatment. This means directing radiation precisely at the affected area, whether that’s an eye socket, a salivary gland, a patch of skin, or a group of lymph nodes. Radiation is highly effective for localized MZL and often curative. It’s a relatively short course of treatment and is generally well tolerated, with side effects limited mostly to the area being treated.
Advanced Disease: Chemotherapy and Immunotherapy
When MZL has spread beyond a single site or region, systemic therapy becomes the standard approach. The most commonly used first-line options combine chemotherapy with rituximab, an immunotherapy drug that targets a protein called CD20 on the surface of lymphoma cells.
The preferred regimens according to current guidelines include bendamustine with rituximab (often called BR), RCHOP (a four-drug chemotherapy combination with rituximab), and CVP with rituximab. Among these, the BR combination has strong supporting data. In a study of 65 previously untreated patients, the estimated six-year progression-free survival rate was about 72%, and among those who achieved a complete response, nearly 90% remained disease-free past five years. The most common side effects were low white blood cell counts (affecting roughly half of patients), fatigue (about 23%), and nausea (about 18%).
For patients who may not tolerate chemotherapy well, rituximab alone is an option, as is lenalidomide combined with rituximab. These tend to be gentler but may not produce responses as deep or durable as the combination chemotherapy regimens.
Splenic MZL: Rituximab Over Surgery
Splenic MZL has historically been treated with splenectomy, removing the spleen surgically. This relieves symptoms quickly and often improves blood counts. But rituximab monotherapy has increasingly replaced surgery as the go-to treatment, and the data supports that shift.
In a head-to-head comparison, rituximab and splenectomy produced similar overall response rates (95% vs. 85%), but rituximab achieved deeper responses. About 45% of rituximab-treated patients had a true complete response, compared with splenectomy patients who often still had circulating lymphoma cells and persistent bone marrow involvement afterward. Five-year overall survival favored rituximab as well: 92% compared to 77% for splenectomy, and five-year progression-free survival was 73% versus 58%. Rituximab also spares you the lifelong infection risk that comes with losing your spleen, making it the preferred choice for most patients.
Relapsed or Resistant Disease
If MZL comes back after initial treatment or doesn’t respond to it, several effective options exist. One important class of drugs targets a protein called BTK, which lymphoma cells rely on to survive and grow.
Zanubrutinib received FDA accelerated approval in 2021 for adults with relapsed or refractory MZL who have already received at least one rituximab-based treatment. In clinical trials, response rates ranged from 56% to 80%, with about 20% of patients achieving a complete response. It’s taken as a daily oral pill, which many patients prefer over intravenous chemotherapy. Ibrutinib, an older BTK inhibitor, is also approved in this setting, though zanubrutinib tends to have a more favorable side effect profile.
For patients who relapse, doctors may also consider retreating with a different chemotherapy-rituximab combination than what was used initially, or switching to lenalidomide with rituximab if it wasn’t used upfront.
CAR T-Cell Therapy for Heavily Treated Patients
In December 2025, the FDA approved the first CAR T-cell therapy for MZL. This treatment, lisocabtagene maraleucel, is available for adults who have relapsed after or failed at least two prior lines of therapy. CAR T-cell therapy involves collecting your own immune cells, genetically engineering them to recognize and attack lymphoma cells, and infusing them back into your body as a single treatment.
The results in the approval trial were striking: 95.5% of patients responded, and 62.1% achieved a complete response with no detectable lymphoma on imaging. These responses held up over a median follow-up of nearly 22 months. Almost half the patients in the trial had particularly aggressive disease, either progressing within two years of diagnosis or having lymphoma that was refractory to prior treatment. CAR T-cell therapy does carry significant short-term risks, including immune reactions that require close monitoring in a specialized center, but it represents a powerful option for patients who have run through other treatments.
Transformation Risk
One concern with any slow-growing lymphoma is the possibility of it transforming into a more aggressive cancer, specifically diffuse large B-cell lymphoma. In MZL, this risk exists but is relatively low. A large population-based study found that the 10-year cumulative transformation rate was about 2.2% overall. The risk varies by subtype: extranodal MZL has the lowest rate at 1.5% over 10 years, nodal MZL sits at 2.7%, and splenic MZL carries the highest risk at 5.8%. Transformation changes the treatment approach significantly, typically requiring more aggressive chemotherapy regimens. New or rapidly worsening symptoms, a sudden spike in a blood marker called LDH, or fast-growing lymph nodes can all signal transformation and warrant prompt evaluation.